Scholars Central

ArticlePublished 31 Dec 2025

Efficacy and Tolerability of CDK4/6 Inhibitors in Patients with HR+/HER2â?? Metastatic Breast Cancer: Real-World Data

Authors: Abir Oufrid, Basma Aabboub, Diango Keita, Sara Nejjari, Samia El Hakym, Hafssa El Hilali, Chaymae Chbihi, Lamiae Amaadour, Karima Oualla, Zineb Benbrahim, Samia Arifi, Nawfel Mellas

Onkologia i Radioterapia

Volume 19 · Issue 12 · Pages 1–4

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Introduction: Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors, in combination with hormone therapy, are currently the standard treatment for hormone receptor–positive, HER2-negative (HR+/HER2−) metastatic breast cancer. Although their efficacy has been demonstrated in randomized clinical trials, real-world data remain limited, particularly in populations underrepresented in pivotal studies. The objective of this study was to evaluate, in a real-world setting, the efficacy and Tolerability of CDK4/6 inhibitors in patients with HR+/HER2− metastatic breast cancer. Methods: This was a retrospective study of patients admitted to the medical oncology department at CHU HASSAN II Hospital in Fès, who received CDK4/6 inhibitors for HR+/HER2− metastatic breast cancer over a six- Year period, from 2018 to 2023, regardless of the date of their first consultation. Results: Thirty-two patients were included in our study, of whom 54% were postmenopausal at diagnosis. The mean age was 52.42 years (range: 32–93), 19% had a family history of cancer, and 81% had an ECOG Performance status of 1. The most frequent metastatic site was bone, observed in 75% of patients— solitary in 6% and associated with other sites in 69%. Prior treatments had been administered to 56% of patients, including radical mastectomy (68%), adjuvant chemotherapy (28%), radiotherapy (62%), or adjuvant hormone therapy (100%). The hormone therapy administered was based on palbociclib and letrozole. CDK4/6 inhibitors were used as first-line therapy in 79% of patients and after prior Treatment in 21%. The mean follow-up duration was 38.4 months, with a mean progression-free Survival of 20.88 months. Neutropenia was the most frequently observed adverse event, followed by fatigue, anemia, rash, and thrombocytopenia. Neutropenia and thrombocytopenia were the most Severe side effects. Conclusion: In routine clinical practice, CDK4/6 inhibitors combined with hormone therapy demonstrate significant clinical efficacy and an acceptable tolerability profile in patients with HR+/HER2− metastatic breast cancer. These results confirm the translatability of clinical trial data to real-world settings and support the use of these treatments as a therapeutic cornerstone in this indication.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Onkologia i Radioterapia.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalOnkologia i Radioterapia
  • SubjectOncology & Cancer
  • BylineArticles whose byline prints “Abir Oufrid”
  • BylineArticles whose byline prints “Basma Aabboub”
  • BylineArticles whose byline prints “Diango Keita”
  • BylineArticles whose byline prints “Sara Nejjari”
  • BylineArticles whose byline prints “Samia El Hakym”
  • BylineArticles whose byline prints “Hafssa El Hilali”
  • BylineArticles whose byline prints “Chaymae Chbihi”
  • BylineArticles whose byline prints “Lamiae Amaadour”